Kazama T, Mizuno I, Takamine T, Umeda K, Terada T, Ishikawa S, Fuse H, Katayama T
Department of Urology, School of Medicine, Toyama Medical and Pharmaceutical University.
Hinyokika Kiyo. 1990 Dec;36(12):1423-7.
We evaluated the effect of anti-androgen therapy for benign prostatic hypertrophy on 33 patients who had undergone transrectal prostatic ultrasonography both before and after administration of anti-androgenic drugs in our clinic. Patients treated with chlormadinone acetate (CMA) orally, or TSAA-291 intramuscularly showed a significant reduction in the prostatic weight. However, this reduction was not correlated with the degree of symptomatic improvement. In addition, patients who showed no symptomatic improvement despite a reduction in the prostatic weight often had prostatic stones or small inflammatory cell infiltrations in their prostatic tissue. Therefore, the coexistence of prostatitis or bladder neck obstruction with prostatic hypertrophy may contribute to the lack of symptomatic improvement in such patients.
我们评估了抗雄激素疗法对良性前列腺增生的疗效，研究对象为33例在我院接受抗雄激素药物治疗前后均进行经直肠前列腺超声检查的患者。口服醋酸氯地孕酮（CMA）或肌肉注射TSAA-291进行治疗的患者，其前列腺重量显著减轻。然而，这种减轻与症状改善程度无关。此外，尽管前列腺重量减轻但无症状改善的患者，其前列腺组织中常伴有前列腺结石或少量炎性细胞浸润。因此，前列腺炎或膀胱颈部梗阻与前列腺增生并存，可能是这类患者缺乏症状改善的原因。
